Mai Capital Management 89bio, Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in 89bio, Inc. stock. As of the latest transaction made, Mai Capital Management holds 1,000 shares of ETNB stock, worth $9,610. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$9,610% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
173Shares Held
125MCall Options Held
78.7KPut Options Held
979K-
Janus Henderson Group PLC London, X016.5MShares$159 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$136 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$98 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$71.9 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$67.4 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $447M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...